Announced
Completed
Synopsis
Tees River, a hedge fund, led a funding round in Ionetix, a cyclotron technology innovator and isotope manufacturer for diagnostic and therapeutic applications, with participation from Eli Lilly and Company, a pharmaceutical company. Financial terms were not disclosed. “Our experience with other critical resources enabled us to understand the significant supply constraints facing the growing radiotherapeutic space. We are pleased to further support Ionetix as they scale supply of cyclotron-produced alpha-emitters," Sean Benson, Tees River Founder and Chief Investment Officer.
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.